STACKD summary
Limited human dataSemax, Selank, and Noopept: the Russian nootropic peptides
Decades of domestic clinical use, but almost no independent international replication.
Plain-language summary
Semax, Selank, and Noopept are the three peptides most often grouped together as “Russian nootropics.” All three were developed by Russian research institutes, are registered as prescription drugs in Russia for specific neurological or psychiatric indications, and have real human trial data behind them—Semax for stroke recovery, Selank for generalized anxiety, Noopept for post-stroke and post-injury cognitive impairment. The honest caveat: almost all of that trial data comes from a small number of Russian research groups, using study designs (open-label, unblinded, or small-sample) that would be considered preliminary by international standards, and none has been through the kind of large, independent, multinational replication that semaglutide or tirzepatide have.
What was studied
Human trials in clinical (not healthy-volunteer) populations: Semax in acute ischemic stroke and optic nerve conditions; Selank in generalized anxiety disorder and neurasthenia, compared against benzodiazepines; Noopept in post-stroke and post-traumatic mild cognitive impairment, compared against piracetam.
Key takeaways
- All three have decades of domestic (Russian) prescription use for specific neurological/psychiatric conditions, which is more real-world human exposure than most “research peptides” in this space.
- Selank's anxiolytic effect in trials was reported as comparable to benzodiazepines like medazepam and phenazepam, without the sedation or dependence typically associated with that drug class.
- Semax's stroke trials measured a hard clinical endpoint (neurological deficit progression), not just a subjective cognitive-enhancement claim.
- Noopept was tested in patients recovering from brain injury or stroke, not in healthy people seeking cognitive enhancement—a meaningfully different population than most online use cases.
Multi-study synthesis
Read together, these three peptides tell a coherent story: a single research tradition producing plausible, mechanistically distinct compounds (an ACTH-derived neuropeptide, a tuftsin-derived anxiolytic, and a piracetam-derived dipeptide) that have accumulated real, decades-long clinical use in one country without ever going through the kind of large-scale, independently replicated trial program that would let the rest of the world evaluate them with confidence. That's a different—and arguably more credible—starting point than most gray-market research peptides, but it still falls well short of “proven.”
Limitations & what we don't know
- Trial designs are frequently open-label or non-randomized rather than double-blind, placebo-controlled RCTs by modern international standards.
- Nearly all of the literature for all three compounds comes from overlapping Russian research groups, with little independent Western replication.
- None of the three is FDA-approved; none has gone through a large multinational phase 3 program.
- Trial populations are stroke, anxiety-disorder, or brain-injury patients—not healthy people optimizing cognition, which is how these are mostly discussed online.
Sources
Primary citations behind this summary. External links are provided for verification—read them yourself before drawing conclusions.
- 1.Semax in Acute Ischemic Stroke: Effects on Neurological Deficit and Recovery
2007 · human
Multicenter trial reported reduced neurological deficit progression in 184 stroke patients.
- 2.Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia
2008 · human
Anxiolytic effect comparable to medazepam, plus antiasthenic effects.
- 3.A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders
2014 · human
Anxiolytic and mild nootropic effects lasting up to a week post-dose.
- 4.Noopept in the treatment of mild cognitive impairment in patients with stroke
2011 · human
Open prospective study found cognitive improvement in stroke patients after 2 months.
- 5.A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment
2008 · human
Comparative trial against piracetam in vascular/traumatic brain disease patients.